Paper Details

  1. Home
  2. Paper Details

Is the overall survival for older adults with AML finally improving?

Author: LancetJeffrey E

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This article discusses the treatment of acute myeloid leukemia (AML) in older adults, highlighting the challenges of poor survival outcomes and the promise of newer agents like CPX-351, glasdegib, and venetoclax.
Paper Details　
Original Abstract of the Article :
Older adults with acute myeloid leukemia (AML) traditionally have very poor survival outcomes. Those who receive only supportive care have worse overall survival than those who undergo treatment, regardless of treatment type, and improvements in overall survival in the last several decades are large...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.beha.2018.09.005

データ提供：米国国立医学図書館（NLM）

Improving Survival for Older Adults with AML: A Glimpse of Hope

Acute myeloid leukemia (AML) is a serious blood cancer, and older adults often face particularly challenging treatment options. This research reviews the current state of AML treatment for older patients, focusing on the potential benefits of newer agents. The researchers discuss how new drugs like CPX-351, glasdegib, and venetoclax may improve survival outcomes for older adults with AML. This research is important because it offers hope for better treatment options for this vulnerable patient population.

Newer Agents: A Shift in Treatment Landscape

The research highlights the potential of newer agents to improve overall survival rates in older adults with AML. These drugs, by targeting specific pathways involved in AML development, offer a new approach to treatment. The researchers' findings suggest that these newer agents could significantly impact the treatment landscape for older adults with AML.

Navigating the Treatment Options for AML

This research emphasizes the importance of collaborating with healthcare providers to make informed decisions about AML treatment. It highlights the need for individualized treatment plans that take into account the patient's age, health status, and overall goals. This research also underscores the importance of ongoing research to develop more effective and less toxic treatment options for older adults with AML.

Dr. Camel's Conclusion

This research provides a glimmer of hope for older adults diagnosed with AML. The promising potential of newer agents suggests that the treatment landscape for this challenging disease is evolving. It's a reminder that ongoing research and innovation are crucial for improving the lives of those affected by cancer. We can be hopeful that future research will lead to even more effective treatment options for this vulnerable population.

Date :
  1. Date Completed 2019-06-20
  2. Date Revised 2019-06-20
Further Info :

Pubmed ID

30466753

DOI: Digital Object Identifier

10.1016/j.beha.2018.09.005

Related Literature

Article Analysis
・Effects of glasdegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.